Evidence map›Paper›PMID 34453104›Full record

ArticleJournal of human hypertension2022

MicroRNA-132 may be associated with blood pressure and liver steatosis-preliminary observations in obese individuals.

Nina Eikelis, John B Dixon, Elisabeth A Lambert, Geula Hanin, Yonat Tzur, David S Greenberg, Hermona Soreq, Francine Z Marques, Michael T Fahey, Geoffrey A Head and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of human hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. The pharmaco-epigenetics of hypertension: a focus on microRNA.Molecular and cellular biochemistry · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Nina EikelisIverson Health Innovation Research Institute and School of Health Sciences, Swinburne University of Technology, Melbourne, VIC, Australia.
John B DixonIverson Health Innovation Research Institute and School of Health Sciences, Swinburne University of Technology, Melbourne, VIC, Australia.
Elisabeth A LambertIverson Health Innovation Research Institute and School of Health Sciences, Swinburne University of Technology, Melbourne, VIC, Australia.
Geula HaninDepartment of Genetics, University of Cambridge, Cambridge, UK.
Yonat TzurThe Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
David S GreenbergThe Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Hermona SoreqThe Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0000-0002-0955-526X
Francine Z MarquesHypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash University, Melbourne, VIC, Australia.ORCID 0000-0003-4920-9991
Michael T FaheyIverson Health Innovation Research Institute and School of Health Sciences, Swinburne University of Technology, Melbourne, VIC, Australia.
Geoffrey A HeadBaker Heart & Diabetes Institute, Melbourne, VIC, Australia.
Markus P SchlaichBaker Heart & Diabetes Institute, Melbourne, VIC, Australia.ORCID 0000-0002-1765-0195
Gavin W LambertIverson Health Innovation Research Institute and School of Health Sciences, Swinburne University of Technology, Melbourne, VIC, Australia. glambert@swin.edu.au.ORCID 0000-0003-0315-645X
Baker Heart and Diabetes Institute · AUHebrew University of Jerusalem · ILMonash University · AUSwinburne University of Technology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent findings in experimental models have shown that the microRNA miR-132 (mir-132) is an important regulator of liver homeostasis and lipid metabolism. We aimed to assess miR-132 expression in liver and fat tissues of obese individuals and examine its association with blood pressure (BP) and hepatic steatosis. We examined obese individuals undergoing bariatric surgery for weight loss (n = 19). Clinical and demographic information was obtained. Quantitative PCR was performed to determine tissue expression of miR-132 in liver and subcutaneous and visceral fat biopsies obtained during bariatric surgery. Liver biopsies were read by a single liver pathologist and graded for steatosis, inflammation and fibrosis. Participants (aged 39 ± 8.1 years) had a body mass index (BMI) of 42 ± 4.5 kg/m

Indexed as

Fatty LiverMicroRNAsBlood PressureHumansObesityTriglyceridesMicroRNAsMIRN132 microRNA, humanTriglycerides

Identifiers

PMID34453104
OpenAlexW3195032599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.